Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
42 studies found for:    " March 19, 2008":" April 18, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
Condition: HIV-Associated Lipodystrophy Syndrome
Interventions: Drug: Standard continuous antiretroviral therapy;   Drug: CD-4 guided therapy interruption;   Drug: Viral load driven treatment interruption
2 Unknown  Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone
Conditions: HIV Infections;   HIV-Associated Lipodystrophy Syndrome
Intervention:
3 Completed
Has Results
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Conditions: HIV -1 Infection;   HIV Infections
Interventions: Drug: PRO 140 (humanized monoclonal antibody to CCR5);   Drug: Placebo Comparator
4 Completed
Has Results
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
Conditions: HIV Infections;   Cardiovascular Disease;   Insulin Resistance;   HIV Lipodystrophy;   The Metabolic Syndrome
Interventions: Drug: Pioglitazone;   Behavioral: Exercise Training
5 Recruiting Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)
Conditions: HIV-hepatitis Co-infection;   HIV Infections
Intervention:
6 Completed HIV Prevention With the Mentally Ill
Condition: HIV Infections
Interventions: Behavioral: Skills Building with Motivational Interviewing;   Behavioral: Skills Building
7 Completed Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
Condition: HIV Infections
Interventions: Drug: Raltegravir and Lopinavir/ritonavir;   Drug: Raltegravir, emtricitabine, tenofovir
8 Completed Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
Conditions: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting;   HIV Infections
Interventions: Drug: Dronabinol;   Drug: Placebo
9 Completed Effectiveness of an Abstinence-Only HIV/Sexually Transmitted Disease Risk-Reduction Intervention for Young African-American Adolescents
Conditions: HIV Infections;   Sexually Transmitted Diseases
Interventions: Behavioral: Abstinence-only HIV/STD risk-reduction intervention;   Behavioral: Safer-sex-only HIV/STD risk-reduction intervention;   Behavioral: Long comprehensive HIV/STD risk-reduction intervention;   Behavioral: Short comprehensive HIV/STD risk-reduction intervention;   Behavioral: Health promotion control intervention
10 Completed Effectiveness of a Risk Reduction Program in Preventing the Transmission of HIV and Sexually Transmitted Diseases in African-American Couples
Conditions: HIV Infections;   Sexually Transmitted Disease
Interventions: Behavioral: Eban HIV/STD Risk Reduction Intervention;   Behavioral: Eban Health Promotion Intervention
11 Completed
Has Results
Raltegravir Therapy for Women With HIV and Fat Accumulation
Conditions: HIV Infections;   Lipodystrophy
Intervention: Drug: raltegravir
12 Unknown  Effectiveness of Interactive Virtual Environment Games in Reducing Risky Sexual Behavior Among Men Who Have Sex With Men (The SOLVE-IT Study)
Condition: HIV Infections
Intervention: Behavioral: Socially Optimized Learning in a Virtual Environment (SOLVE)-IT
13 Completed Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: Emtricitabine/tenofovir disoproxil fumarate
14 Unknown  A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
Conditions: HIV Infections;   Hepatitis B Virus
Intervention:
15 Active, not recruiting Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon
Condition: HIV Infections
Interventions: Drug: Treatment initiation for HIV-1 group O infected patients;   Drug: Treatment initiation for HIV-1 group M infected patients
16 Completed TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
Condition: HIV
Intervention: Drug: TMC114; darunavir; Prezista
17 Completed Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
Condition: Human Immunodeficiency Virus
Intervention: Drug: lopinavir/ritonavir
18 Completed Adult Sexual Risk Behavior Among Women With a History of Childhood Sexual Abuse
Conditions: HIV Infections;   Child Abuse, Sexual
Interventions: Behavioral: Information-Motivation-Behavioral Skills model;   Behavioral: Traumagenic Dynamics model
19 Completed Effectiveness of HIV/Sexually Transmitted Infection Training for Physicians in China
Conditions: HIV Infections;   Gonorrhea;   Chlamydia
Interventions: Behavioral: Physician Ai Shi Zi training;   Drug: Standard care;   Behavioral: Patient risk-reduction counseling
20 Completed Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1;   Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years